22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
The socioeconomic fallout of COVID-19 represents an enormous challenge for the construction sector, ...
Read More >
Health Care Company Rescinded Job Offer Because She Was Pregnant, Federal Agency Charged - PHOENIX...
Read More >
As 2019 comes to an end, we are pleased to present our traditional End of Year Plan Sponsor “To Do”...
Read More >
Every player interested or already active in the German market needs to have a working knowledge of ...
Read More >
Private equity-backed takeovers of listed companies in Western Europe have enjoyed several strong ye...
Read More >
In this episode of Trekking Through Compliance, we consider the episode Wink of an Eye which aired o...
Read More >